PURPOSE: Müllerian inhibiting substance (MIS) causes Müllerianduct regression in mammalian, avian, and reptilian embryos; MIS also inhibits growth in vitro of Müllerian-derived cell lines and primary cells from human ovarian carcinomas. We hypothesize that highly purified MIS delivered parenterally inhibits ovarian cancer in vivo. EXPERIMENTAL DESIGN: To test the efficacy of highly purified MIS against ovarian cancer cell lines in vivo, we treated immunosuppressed mice with MIS after implanting OVCAR 8 or IGROV 1 human ovarian cancer cells beneath the renal capsules and measured tumor volume over time. Animals were treated with daily injections of 10 micro g of purified exogenous recombinant human MIS or by endogenous MIS secreted from cells growing on biodegradable mesh. RESULTS: The average graft size ratio (change in size compared with starting size) of the OVCAR 8 tumor implants was larger in the control animals than in animals treated for 2 weeks (P < 0.019) or 3 weeks (P < 0.001) with parenteral MIS, or after treating with MIS produced from transfected cells, which impregnated the biodegradable mesh (P = 0.02). The average graft size ratio of the IGROV 1 tumors was also larger in the control animals than in those treated with injected MIS (P = 0.0174). CONCLUSIONS: Highly purified recombinant human MIS, delivered parenterally, or MIS produced endogenously causes inhibition of human ovarian cancer cell lines in vivo, providing convincing preclinical evidence to support the use of MIS as a parenteral agent for the treatment of ovarian cancer.
PURPOSE: Müllerian inhibiting substance (MIS) causes Müllerianduct regression in mammalian, avian, and reptilian embryos; MIS also inhibits growth in vitro of Müllerian-derived cell lines and primary cells from humanovarian carcinomas. We hypothesize that highly purified MIS delivered parenterally inhibits ovarian cancer in vivo. EXPERIMENTAL DESIGN: To test the efficacy of highly purified MIS against ovarian cancer cell lines in vivo, we treated immunosuppressed mice with MIS after implanting OVCAR 8 or IGROV 1 humanovarian cancer cells beneath the renal capsules and measured tumor volume over time. Animals were treated with daily injections of 10 micro g of purified exogenous recombinant humanMIS or by endogenous MIS secreted from cells growing on biodegradable mesh. RESULTS: The average graft size ratio (change in size compared with starting size) of the OVCAR 8 tumor implants was larger in the control animals than in animals treated for 2 weeks (P < 0.019) or 3 weeks (P < 0.001) with parenteral MIS, or after treating with MIS produced from transfected cells, which impregnated the biodegradable mesh (P = 0.02). The average graft size ratio of the IGROV 1 tumors was also larger in the control animals than in those treated with injected MIS (P = 0.0174). CONCLUSIONS: Highly purified recombinant humanMIS, delivered parenterally, or MIS produced endogenously causes inhibition of humanovarian cancer cell lines in vivo, providing convincing preclinical evidence to support the use of MIS as a parenteral agent for the treatment of ovarian cancer.
Authors: Elizabeth J Renaud; David T MacLaughlin; Esther Oliva; Bo R Rueda; Patricia K Donahoe Journal: Proc Natl Acad Sci U S A Date: 2004-12-23 Impact factor: 11.205
Authors: Alba Rodriguez-Garcia; Prannda Sharma; Mathilde Poussin; Alina C Boesteanu; Nicholas G Minutolo; Sarah B Gitto; Dalia K Omran; Matthew K Robinson; Gregory P Adams; Fiona Simpkins; Daniel J Powell Journal: Mol Ther Date: 2019-12-06 Impact factor: 11.454
Authors: V Gupta; J L Carey; H Kawakubo; A Muzikansky; J E Green; P K Donahoe; D T MacLaughlin; S Maheswaran Journal: Proc Natl Acad Sci U S A Date: 2005-02-22 Impact factor: 11.205
Authors: Henry L Chang; Rafael Pieretti-Vanmarcke; Fotini Nicolaou; Xianlin Li; Xiaolong Wei; David T MacLaughlin; Patricia K Donahoe Journal: Gynecol Oncol Date: 2010-11-06 Impact factor: 5.482
Authors: Seong Jin Hwang; Min Jung Suh; Joo Hee Yoon; Mee Ran Kim; Ki Sung Ryu; Suk Woo Nam; Patricia K Donahoe; David T Maclaughlin; Jang Heub Kim Journal: Int J Oncol Date: 2011-05-13 Impact factor: 5.650
Authors: Jae Yen Song; Hyun Hee Jo; Mee Ran Kim; Young Oak Lew; Ki Sung Ryu; Jung Ho Cha; Chang Suk Kang; Patricia K Donahoe; David T MacLaughlin; Jang Heub Kim Journal: Int J Oncol Date: 2012-02-14 Impact factor: 5.650
Authors: Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Aurelio Barricarte; Louise A Brinton; Brian L Egleston; Roni T Falk; Renée T Fortner; Kathy J Helzlsouer; Yutang Gao; Annika Idahl; Rudolph Kaaks; Vittorio Krogh; Melissa A Merritt; Eva Lundin; N Charlotte Onland-Moret; Sabina Rinaldi; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Carlotta Sacerdote; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley S Tworoger; Kala Visvanathan; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Joanne F Dorgan Journal: Int J Cancer Date: 2017-10-04 Impact factor: 7.396
Authors: Thanh U Barbie; David A Barbie; David T MacLaughlin; Shyamala Maheswaran; Patricia K Donahoe Journal: Proc Natl Acad Sci U S A Date: 2003-12-11 Impact factor: 11.205